Exelixis, Inc. Files Q1 2025 10-Q Report
Ticker: EXEL · Form: 10-Q · Filed: May 13, 2025 · CIK: 939767
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Exelixis Q1 2025 10-Q filed. Financials and ops update.
AI Summary
Exelixis, Inc. filed its 10-Q for the period ending April 4, 2025. The company, based in Alameda, CA, operates in the biological products sector. Key financial data and operational details for the first quarter of fiscal year 2025 are presented in this filing.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for Exelixis, Inc., crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- 2025 Q1 — Reporting Period (First quarter of fiscal year 2025)
- 043257395 — EIN (Employer Identification Number)
Key Players & Entities
- EXELIXIS, INC. (company) — Filer
- ALAMEDA (location) — Business Address City
- 20250404 (date) — Conformed Period of Report
- 20250513 (date) — Filed as of Date
FAQ
What is the primary business of Exelixis, Inc.?
Exelixis, Inc. is primarily involved in Biological Products (No Diagnostic Substances) as indicated by its SIC code [2836].
What is the filing date and reporting period for this 10-Q?
This 10-Q was filed on 20250513 and reports on the period ending 20250404.
Where is Exelixis, Inc. headquartered?
Exelixis, Inc.'s business and mailing address is in Alameda, CA.
What is the fiscal year end for Exelixis, Inc.?
The fiscal year end for Exelixis, Inc. is January 2nd.
What are the main segments reported by Exelixis, Inc.?
The filing indicates segments such as 'Product' and 'Collaboration'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding EXELIXIS, INC. (EXEL).